请输入关键字
确定
程辉
北京协和医学院助理教授(长准聘系列),研究员
中以人群医学“一带一路”联合实验室副主任
研究概述
教育经历
工作经历
主持项目
代表性成果及文章

作为最早被应用于临床的成体干细胞,造血干细胞(HSC)功能和分化模式一直以来是研究的热点。我们实验室的研究目标是明确HSC在稳态和疾病状态下的内外调控机制,揭示微环境在其中的变化规律继而对HSC的影响机理,探讨HSC选择性保护的分子机制,以期为白血病的治疗提供新的思路和策略。

2012 中国医学科学院&北京协和医学院内科学博士

2007 浙江大学生物信息学学士


2020-至今   协和准长聘助理教授,研究员

2015-2020  中国医学科学院血液病医院(中国医学科学院血液学研究所)副研究员

2016-2017  以色列魏茨曼科学院访问学者

2013-2015  中国医学科学院血液病医院(中国医学科学院血液学研究所)科研助理




1.    国家重点研发计划,2020YFE0203000,克隆性造血相关疾病的防控与机制研究,2020.11-2023.08

2.    国家自然科学基金优秀青年科学基金项目,81922002,造血干细胞的生理与病理调控机制,2020.01-2022.12

3.    国家自然科学基金面上项目,81870086,单细胞尺度解析白血病下造血干/祖细胞及其微环境的变化规律及机制,2019.01-2022.12

4.    国家自然科学基金青年科学基金项目,81400077,Egr3调控造血干细胞功能的机制研究,2015.01-2017.12

5.    2019年天津市杰出青年科学基金

6.    2018年首批天津市“青年医学新锐”

7.    2018年第三批天津市“青年拔尖人才支持计划”

8.    中国医学科学院医学与健康科技创新工程,细胞异质性的表观遗传调控机理,2017.01-2020.12,子课题负责人




1.        Zheng Z#, He H#, Tang X#, Zhang H#, Gou F#, Yang H#, Cao J, Shi S, Yang Z, Sun G, Xie X, Zeng Y, Wen A, Lan Y, Zhou J, Liu B*, Zhou B*, Cheng T*, Cheng H*. Uncovering the emergence of HSCs in the human fetal bone marrow by single cell RNA-seq analysis. Cell Stem Cell. 2022

2.        Sun G#, Gu Q#, Zheng J*, Cheng H*, Cheng T*. Emerging roles of extracellular vesicles in normal and malignant hematopoiesis. Journal of Clinical Investigation. 2022.

3.        Yang S#, Sun G#, Wu P#, Chen C#, Kuang Y, Liu L, Zheng Z, He Y, Gu Q, Lu T, Zhu C, Wang F, Gou F, Yang Z, Zhao X, Yuan S, Yang L, Lu S, Li Y, Lv X, Dong F, Ma Y, Yu J, Ng L, Shi L, Liu J*, Shi L*, Cheng T*, Cheng H*. WDR82-binding long non-coding RNA lncEry controls mouse erythroid differentiation and maturation. Journal of Experimental Medicine. 2022

4.        Duan H, Cheng T*, Cheng H*. Spatially resolved transcriptomics: advances and applications. Blood Science. 2022

5.        Wang F #, He J#, Liu S#, Gao A, Yang L, Sun G, Ding W, Li C, Wang F, Wang X, Zhu P, Hao S, Ma Y*, Cheng H*, Yu J*, Cheng T*. Comprehensive RNA editome reveals that edited Azin1 partners with DDX1 to enable hematopoietic stem cell differentiation. Blood. 2021

6.        Yuan S, Sun G, Zhang Y, Dong F, Cheng H*, Cheng T*. Understanding the ‘SMART’ features of hematopoietic stem cells and beyond. Science China Life sciences. 2021

7.        Huang D#, Sun G#, Hao X#, He X#, Zheng Z, Chen C, Yu Z, Xie L, Ma S, Liu L, Zhou B, Cheng H*, Zheng J*, and Cheng T*. ANGPTL2-containing small extracellular vesicles from vascular endothelial cells accelerate leukemia progression. Journal of Clinical Investigation. 2021;131(1).

8.        Wang T#, Xia C#, Weng Q, Wang K, Dong Y, Hao S, Dong F, Liu X, Liu L, Geng Y, Guan Y, Du J, Cheng T, Cheng H*, Wang J*. Loss of Nupr1 promotes engraftment by tuning the quiescence threshold of hematopoietic stem cell repository via regulating p53-checkpoint pathway. Haematologica. 2020.

9.        Zhang C#, Xu Z#, Yang S#, Sun G#, Jia L, Zheng Z, Gu Q, Tao W*, Cheng T*, Li C* and Cheng H*. tagHi-C reveals 3D chromatin architecture dynamics during hematopoiesis. Cell Reports. 2020;32(13)

10.    Dong F, Cheng H*, Ema H*, Cheng T*. Probing the fate of transplanted hematopoietic stem cells: is the combinational approach "FIT" for purpose? Science China Life sciences. 2020;63(11):1755-8.

11.    Dong F#, Hao S#, Zhang S#, Zhu C#, Cheng H#, et al. Differentiation of transplanted haematopoietic stem cells tracked by single-cell transcriptomic analysis. Nature Cell Biology. 2020;22(6):630-9.

12.    Xia C#, Wang T#, Cheng H#, et al. Mesenchymal stem cells suppress leukemia via macrophage-mediated functional restoration of bone marrow microenvironment. Leukemia. 2020;34(9):2375-83.

13.    Ma S#, Sun G#, Yang S, Ju Z*, Cheng T*, Cheng H.*. Effects of telomere length on leukemogenesis. Science China Life sciences. 2020;63(2):308-11

14.    Su M, Cheng H*, Cheng T*. Preleukemic stem cells: leave it or not? Blood Science. 2020.

15.    Wang Y#, Lu T#, Sun G#, Zheng Y#, Yang S, Zhang H, Hao S, Liu Y, Ma S, Zhang H, Ru Y, Gao S, Yen K*, Cheng H*, Cheng T*. Targeting of apoptosis gene loci by reprogramming factors leads to selective eradication of leukemia cells. Nature communications. 2019;10(1):5594.

16.    Gao A#, Gong Y#, Zhu C, Yang W, Li Q, Zhao M, Ma S, Li J, Hao S*, Cheng H*, Cheng T*. Bone marrow endothelial cell-derived interleukin-4 contributes to thrombocytopenia in acute myeloid leukemia. Haematologica. 2019;104(10):1950-61.

17.    Cheng H#*, Zheng Z#, Cheng T*. New paradigms on hematopoietic stem cell differentiation. Protein & cell. 2019;11(1):34-44.

18.    Cheng H#*, Sun G#, Cheng T*. Hematopoiesis and microenvironment in hematological malignancies. Cell Regen (Lond) 2018;7:22-26

19.    Gong Y, Zhao M, Yang W, Gao A, Yin X, Hu L, Wang X, Xu J, Hao S, Cheng T*, Cheng H*. Megakaryocyte-derived excessive TGFbeta1 inhibits proliferation of normal hematopoietic stem cells in acute myeloid leukemia. Experimental Hematology. 2018;60:40-46

20.    Cheng H, Liu Y, Jia Q, Ma S, Yuan W, Jia H, and Cheng T*. Novel regulators in hematopoietic stem cells can be revealed by a functional approach under leukemic condition. Leukemia. 2016;30:2074-77.

21.    Cheng H, and Cheng T*. 'Waterloo': when normal blood cells meet leukemia. Current opinion in hematology. 2016;23:304-10.

22.    Cheng H#, Hao S#, Liu Y, Pang Y, Ma S, Dong F, Xu J, Zheng G, Li S, Yuan W, Cheng T*. Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation. Blood. 2015;126:1302-13.

23.    Liu Y#, Cheng H#, Gao S, Lu X, He F, Hu L, Hou D, Zou Z, Li Y, Zhang H, Xu J, Kang L, Wang Q, Yuan W, Cheng T*. Reprogramming of MLL-AF9 leukemia cells into pluripotent stem cells. Leukemia. 2014;28:1071-80.